前收市價 | 0.0800 |
開市 | 0.0800 |
買盤 | 0.0000 |
賣出價 | 0.7500 |
拍板 | 12.50 |
到期日 | 2024-06-21 |
今日波幅 | 0.0800 - 0.0800 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 19 |
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.